Data Safety Monitoring Board recommends continuation of Nexstim Plc’s Phase III Stroke Therapy Trial

on 26/09/2015 17:13
Interim data analysis by an independent Data Safety Monitoring Board shows that safety criteria are met and trial should continue without any modifications
Read more

Positive Results for Mainstay Medical’s Clinical Trial of ReActiv8®

on 31/08/2015 11:34
Clinically important, statistically significant, and lasting improvement in pain, disability, and quality of life for people with Chronic Low Back Pain and limited treatment options.
Read more

Mainstay Medical Announces Half Year Financial Results

on 31/08/2015 11:30

Mainstay Medical Announces Additional US Patent Issued

on 26/08/2015 11:26

Nexstim: Key Technology Patent Granted for US

on 11/08/2015 15:52
Strengthened patent estate around Nexstim’s cutting-edge technology
Read more